Duvelisib
Duvelisib is a pharmaceutical drug with 40 clinical trials. Currently 9 active trials ongoing. Historical success rate of 65.0%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
19
Early Stage
15
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
13 of 26 finished
50.0%
13 ended early
9
trials recruiting
40
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Clinical Trials (40)
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 40